Abstract-The extent of processing of type III collagen is assessed, and the proportions of type I and III collagens are estimated in atherosclerotic plaques obtained from the carotid artery, common femoral artery, and aorta. The fraction of type III collagen that had retained its amino-terminal propeptide (pN-collagen) was 42% in the soluble extract but only 0.0081% in the insoluble residue. Taken together, only 0.011% of the type III collagen in whole plaques was in the form of type III pN-collagen. Together with the small amounts of the free propeptides of type I procollagen, this finding indicates a low rate of collagen turnover. The amounts of solubilized telopeptides of type I and III collagens were measured, after heat denaturation and trypsin digestion of the collagenous helix, by specific immunoassays for the corresponding trypsin-generated antigens. The mean proportion of type III collagen was 61% (95% confidence interval, 58% to 65%) in the carotid and femoral artery plaques and 56% (95% confidence interval, 44% to 68%) in the aortic specimens. A ccording to the response-to-injury hypothesis, atherosclerosis is an excessive inflammatory-fibroproliferative response to various forms of insult to the artery wall. It results from focal intimal thickening subsequent to endothelial cell injury and uncontrolled proliferation of smooth muscle cells (SMCs), accompanied by the participation of inflammatory cells and the accumulation of extracellular components (for reviews, see References 1 and 2). The extracellular matrix participates in virtually all aspects of the atherogenic process. The organic matrix of a plaque consists mainly of collagen types I and III, but controversy exists over their contents and changes in their proportions between the healthy and atherosclerotic aorta. [3] [4] [5] [6] [7] [8] [9] [10] A currently unknown proportion of type III collagen still carries the amino-terminal propeptide domain of its precursor, type III procollagen. 11 Regarding atherosclerotic manifestations, we have previously demonstrated increased serum levels of this propeptide, PIIINP, after both streptokinase and tissue plasminogen activator treatments after acute myocardial infarction 12,13 and detected increased serum levels of PIIINP in patients with expanding abdominal aortic aneurysms. Interestingly, the gradient in the PIIINP concentration over the aneurysm sac was significant. 14 These results suggest active collagen metabolism in the vessel walls in these clinical situations.
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The aim here was to assess the proportions and processing of the type I and III collagens present in advanced human atherosclerotic plaques. We used a combination of immunoassays specific for the various domains of type I and III collagens and procollagens and developed a novel method for examining insoluble collagens. Particular attention was paid to the apparent rate of collagen synthesis and to the proportion of partially processed procollagen molecules with the PIIINP part still attached (type III pN-collagen) that can be found on the surface of type III collagen fibers.
Methods

Tissue Samples
Endarterectomy plaques from the carotid artery (nϭ15) and the common femoral artery (nϭ2) and atherosclerotic plaques from the abdominal aorta (nϭ8) were obtained from patients undergoing vascular procedures at the Department of Surgery, Oulu University Hospital. The carotid and femoral specimens were from 12 men and 5 women (mean age, 66.4 years) and the aortic ones from 5 men and 3 women (mean age, 72.9 years). To validate the methods applied, we obtained a piece of healthy aorta from a 29-year-old male cadaver under examination at the Department of Pathology, University of Oulu. The uterine leiomyoma and human placenta were obtained from the Department of Obstetrics and Gynecology, Oulu University Hospital. All of the samples were frozen and stored at Ϫ20°C until processed. The collection of human tissue samples was approved by the ethics committee of the Faculty of Medicine, University of Oulu.
Immunoassays for Type III Collagen
The amino-terminal propeptide of human type III collagen, PIIINP, was measured in soluble extracts and trypsin digests of insoluble tissue residue by radioimmunoassay (Orion Diagnostica), as described previously, 15 using sequential saturation. The samples were diluted 1:1 to 1:20 before analysis.
The cross-linked amino-terminal telopeptide of type III collagen, IIINTP, was analyzed by a novel in-house radioimmunoassay. 16 The IIINTP antigen was purified from trypsin-digested human uterine leiomyoma by gel exclusion chromatography and reverse-phase chromatography on a high-performance liquid chromatography system. The final product was sequenced and its size and purity determined by SDS-polyacrylamide gel electrophoresis (PAGE). The purified antigen was used to raise polyclonal antibodies in rabbits. The dilution of the antiserum used in the assay was 1:400, and the binding of the radiolabeled ( 125 I) antigen was 53%. Aliquots (100 L) of a properly diluted sample were incubated with 200 L of the antiserum dilution and 200 L of 125 I-IIINTP solution for 2 hours at 37°C. Then 0.5 mL of the second antibody in 10% PEG (molecular weight, 6000) was added, and the tubes were incubated at 4°C for 30 minutes. The samples were centrifuged at 2000g for 30 minutes at 4°C, and the radioactivity in the precipitates was counted. Before analysis, the samples were diluted from 1:5 to 1:1000. In addition, an immunoassay for the synthetic peptide SP6, having the sequence DVKSGVAVGGLAG (from Neosystem Laboratories, Strasbourg, France) from the amino-terminal telopeptide of the ␣1-chain of type III collagen, was used to show that practically no immaturely cross-linked telopeptides were present in the tissue digests (see below).
Immunoassays for Type I Collagen
The metabolites of type I collagen were measured using commercially available immunoassays for the PINP, PICP, and ICTP antigens (Orion Diagnostica) as described previously. [17] [18] [19] PINP, the amino-terminal propeptide of type I collagen, was measured in undiluted samples of the soluble extracts, and PICP, the carboxyterminal propeptide of type I collagen, was measured by using dilutions of 1:5 to 1:10. The concentrations of ICTP, the carboxyterminal telopeptide of type I collagen, were analyzed in trypsin digests by using dilutions varying from 1:100 to 1:4000. In addition, an immunoassay for the synthetic peptide SP4, having the sequence SAGFDFSFLPQPPQEKY (Neosystem) derived from the carboxyterminal telopeptide of the ␣1-chain of type I collagen, was analyzed to show that very few immaturely cross-linked telopeptides were present in the tissue digests (see below).
Tissue Preparation
The atherosclerotic plaques (weight, 0.39 to 3.5 g) and sclerotic aortic specimens (0.004 to 34.1 g) were cut into small pieces, and PBS-Tween 20 was added (1 mL/100 mg of wet tissue weight). A piece of healthy human aorta (weight, 21 g) was treated similarly. The samples were homogenized with an Ultra-Turrax homogenizer and centrifuged at 10 000g for 30 minutes. The supernatants were collected for gel filtration and for the PINP, PICP, and PIIINP analyses.
Trypsin Treatment
The insoluble pellets were treated with NaBH 4 (50 mg/g tissue weight) to stabilize the possibly reducible cross-links. Fats were removed by brief washes with acetone/methanol (1:2, vol/vol) and finally with ethanol, followed by centrifugation and collection of the pellet. The insoluble pellets were freeze-dried, weighed, suspended in 0.2 mol/L NH 4 HCO 3 (1 mL/10 mg dry weight), denatured at 70°C for 1 hour, and treated with 1 mg of trypsin per 100 mg of sample. The digestions were performed for 4 hours at 37°C, after which the samples were re-denatured, homogenized, and re-treated overnight with the same amount of trypsin. The residual trypsin activity was destroyed at 70°C, and the samples were centrifuged at 10 000g for 30 minutes. The supernatants were used for the ICTP, IIINTP, and PIIINP analyses.
Preparation of the Calcified Matrix
After the first 2 enzyme digestions, the insoluble pellets were briefly washed with 8 mol/L urea to remove small, colored residues of trypsin-resistant materials, and demineralization was carried out by extraction with 0.5 mol/L EDTA, pH 7.6, twice for 2 days at 4°C. The residue was then washed twice with water and once with 0.2 mol/L NH 4 HCO 3 before freeze-drying. The pellet was weighed, and trypsin digestion was performed as described above. The digests were then centrifuged at 10 000g for 30 minutes, and the supernatants were collected and used for ICTP, IIINTP, and PIIINP analyses.
Gel Exclusion Chromatography
Several plaque samples were analyzed further by gel exclusion chromatography to determine the size and cross-link maturity of the type I and III collagen propeptides and telopeptides.
The supernatants of the homogenates were analyzed on a Sephacryl S-300 column equilibrated in PBS-Tween 20 at a flow rate of 6 mL/h and collecting 2.0-mL fractions. The concentrations of PINP and PICP were analyzed in undiluted fractions and that of the PIIINP, in 1:10 dilution. Absorbances were measured at 280 nm.
Trypsin-digested samples (both noncalcified and calcified) were analyzed on a Sephacryl S-100 column equilibrated in 0.2 mol/L NH 4 HCO 3 , and the concentrations of IIINTP, ICTP, and PIIINP were measured. The dilutions used varied from 1:1 to 1:20 for IIINTP and from 1:5 to 1:100 for ICTP, the analysis for PIIINP being carried out in undiluted fractions.
SDS-Polyacrylamide Gel Electrophoresis
The effect of trypsin digestion on the size of the PIIINP antigen was analyzed by SDS-PAGE in 18% gels under reduced conditions. SDS-PAGE was also used for comparing the sizes of the ICTP and IIINTP antigens purified from the plaques with the corresponding trypsin-derived antigens from human leiomyoma and bone.
Statistical Analyses
The values are expressed as means (with 95% CIs). The statistical analyses were carried out using the SPSS statistical tool and CI analysis. Spearman's rank correlation was used for correlation analysis.
Results
Validation of the Tissue Solubilization Procedure
Before analysis of the clinical samples, the effectiveness of heat denaturation and trypsin digestion for solubilizing the IIINTP and ICTP antigens from the atherosclerotic plaque was tested (Figure 1 ). Trypsin digestion effectively released the antigens from the insoluble matrix within 1 hour, and further digestion did not affect the yield.
Purification of IIINTP and ICTP Antigens From the Plaque
Cross-linked IIINTP was partially purified from 120 mg of trypsin-digested, insoluble plaque matrix in the same way as for the standard IIINTP antigen from uterine leiomyoma (see above). The size of the isolated plaque telopeptide was compared with that of the leiomyoma IIINTP on SDS-PAGE (Figure 2A ). Cross-linked ICTP was also partially purified from the insoluble plaque matrix as described previously, 19 and its size was compared with that of bone ICTP on Figure 2B ). Both of these cross-linked telopeptides were found to be similar to those of the standard antigens isolated from the reference tissues ( Figure 2 ). Also, their elution positions in gel filtration chromatography corresponded to those of the standards (see Figure 5 ). The inhibition curves obtained in the immunoassays were also parallel, indicating complete cross reaction (not shown).
SDS-PAGE (
Effect of Trypsin Digestion on the Antigenicity of Purified PIIINP
PIIINP was purified from human ascitic fluid as described earlier. 15 Enzyme digestion was performed in the same way as for the atherosclerotic samples (propeptide: enzymeϭ1:50 wt/wt), and its effects on the apparent size of the antigen on SDS-PAGE and on the antigenicity in the immunoassay were studied. There was partial cleavage of the propeptide ( Figure  3) , which led to a 50% decrease in its immunoreactivity ( Figure 4) . Consequently, the PIIINP concentration observed in the trypsin digests was multiplied by 2 when calculating the amount of type III pN-collagen in the tissue samples.
Insoluble Collagens in Atherosclerotic Specimens
The soluble extracts of the atherosclerotic tissues contained Ͻ0.1% of the total amounts of the cross-linked telopeptides of type I and III collagens, ICTP and IIINTP, respectively. Thus, up to 99.9% of the type I and III collagens in these tissues is rendered insoluble via cross-linking.
The mean proportion of type III collagen (calculated as a percentage of the sum of types I and III) was 61% in the endarterectomy plaques and 56% in the atherosclerotic aortic specimens ( Table 1 ). The 1 healthy young aorta contained only slightly more type III collagen (72%) than did the rest of the samples. There was a significant correlation between the total amounts of solubilized ICTP and IIINTP antigens (rϭ0.92; PϽ0.01; 95% CI, 0.82 to 0.96). For comparison, in human leiomyoma and placenta, the proportion of type III collagen was 35% and 33%, respectively.
As expected, the proportion of the calcified extracellular matrix varied greatly between the samples (eg, 1% to 60% of IIINTP was found to be calcified). Bearing this large variation in mind, the mean value of IIINTP and ICTP found in the calcified matrix was 18% of the total amount of those cross-linked antigens. Surprisingly, the proportion of type III collagen was practically the same in both the calcified and the noncalcified matrix, being 54% in the calcified fraction. The large variation between the samples is most probably due to different extents of calcification, which affects the weights of the samples but not the proportions of the 2 collagen types. As expected, the healthy aorta did not show any visible calcification.
Sizes of the Cross-Linked Telopeptide Antigens
The IIINTP and ICTP antigens in the atherosclerotic plaques corresponded in size to the trivalent, fully cross-linked peptide standards ( Figure 5 ). The ICTP antigen eluted in 1 peak (fractions 47 to 55), and there were no smaller antigenic forms. This was true both for the calcified and noncalcified phases of the samples. The IIINTP antigen was also eluted in 1 major peak, corresponding to a trivalent, fully cross-linked peptide standard (fractions 37 to 47), but there were also minor amounts of possible divalently cross-linked and noncross-linked forms (fractions 48 to 69).
Amounts and Sizes of Procollagen Propeptides in the Atherosclerotic Specimens
The propeptides of type I procollagen, PINP and PICP, and that of type III procollagen, PIIINP, were measured in extracts that contained soluble, mostly non-cross-linked collagens. In addition, PIIINP was measured in the trypsin digests of both the insoluble matrixes. The concentrations of PINP and PICP in the soluble extract were very low (PINP, 0.13 g/g wet weight; SD, 0.06 g/g; PICP, 1.18 g/g; SD, 0.46 g/g), indicating a very low rate of type I procollagen synthesis in the plaques. Although the concentration of PINP antigenicity in the fractions was almost too low to be analyzed by gel filtration, only authentically cleaved PINP antigen was found to be present ( Figure  6A ). In the case of PICP, almost equal amounts of the intact carboxy-terminal propeptide and the type I pC-collagen were seen ( Figure 6B ).
Approximately 35% of the PIIINP antigen was found in the soluble extract and 65% in the insoluble matrix. Gel filtration analysis indicated that the PIIINP antigen in the soluble fraction was almost always in the form of type III pNcollagen ( Figure 6C ), so that the pN-collagen accounted for 42% of the total type III collagen in the extract (Table 2 ). In the insoluble matrix, however, only 0.0081% of the type III collagen was in the form of pN-collagen. Thus, the overall proportion of type III pN-collagen in the plaques was only 0.011% (Table 2 ). For comparison, in the insoluble matrix of human leiomyoma and placenta, the proportion of type III pN-collagen was 1.4% and 8.5%, respectively.
Discussion
Collagens are important for atherogenesis because they represent the major extracellular component in the plaque and thereby contribute to the occlusive nature of the disease. They also play a significant role in hemostasis and thrombosis by inducing the aggregation of blood platelets. 20 Furthermore, collagens can influence the proliferation and state of differentiation of SMCs in vitro. 21 Several collagen types are known to bind oxidized lipoproteins, and thus accumulation of collagen in the intima may promote lipoprotein accumulation. 22 At least 6 collagen types (I, III, IV, V, VI, and VIII) are present in blood vessels, 23 and a predominance of interstitial collagen types I and III has been documented in atherosclerotic lesions, where they appear to be codistributed in different amounts within all 3 layers of the artery wall. 10, 24 Notwithstanding the considerable advances made in the area relating to arterial collagens of normal and atherosclerotic tissues, the available information remains incomplete and, above all, inconsistent and controversial. 20, 25, 26 The initial work on the status of interstitial collagens 3 suggested that there is a shift in favor of type I collagen in fibrous atherosclerotic lesions compared with the normal arterial wall, where type III collagen predominates. Later results have suggested, however, that type I, not type III, collagen is always the major species, accounting for 55% to 88% of the total content of the 2. 4 -10 One reason for the discrepancies could be analytical problems related to the highly crosslinked state of the vessel wall collagens, which hampers methods in which solubilized materials are quantified. The initial result, a large amount of type III collagen in the healthy aorta, 3 was later criticized in light of the assumption that pepsin solubilizes type III collagen from the vessel wall more easily than it does type I. 27 CNBr digestion of the insoluble matrix suggested that larger amounts of type I collagen than of type III were found, but the CNBr method is also subject to similar errors, since the cleavage of collagen chains can be prevented by methionine oxidation. In addition, the CNBr method is based on simple staining of the cleaved peptides, a procedure that is known to be not optimal for the collagenous sequences.
We used a novel method of type I and III collagen analysis that partially overcomes the problem of insolubility due to cross-linking. It has previously been shown that 99% of type I collagen can be solubilized when the highly insoluble collagenous matrix of dentin is repeatedly heat denatured and digested with trypsin. 28 This solubilization method also works with soft tissues (Figure 1 ), because trypsin effectively cleaves all denatured collagens specifically, after the basic amino acids lysine and arginine. The telopeptide domains containing the cross-links are liberated in a cross-linked state, and their concentrations can be determined by specific immunoassays developed for the trypsin-generated antigens. In addition to trypsin, several other enzymes such as bacterial collagenase, chymotrypsin, and pepsin cleave denatured collagens. Pepsin and chymotrypsin, 29 however, destroy the immunoreaction in the ICTP assay, and they also affect IIINTP antigenicity. Compared with bacterial collagenase, trypsin is more specific, more potent, and more cost-effective. The validity of the telopeptide approach, however, should also be tested for each tissue studied, because the ICTP assay especially 19 measures only trivalently cross-linked forms of type I collagen. Thus, the content of type I collagen in human skin, which contains mainly histidine-derived cross-links, 30 cannot be reliably estimated with this method.
The type I collagen in atherosclerotic plaques was found to be fully cross-linked, since a synthetic peptide (SP4) assay detecting all of the various cross-linked and non-cross-linked forms gave a similar elution profile in gel filtration as did the ICTP assay ( Figures 2B and 5) . Likewise, there was no evidence in the case of type III collagen to indicate that the size, chain composition, or cross-linking was in any way different from that in the trivalently cross-linked IIINTP used as the standard (Figures 2A and 5) . Thus, the present results support those obtained earlier, indicating that type III collagen is at least as abundant as type I collagen in aortic walls. This is not surprising, because genetic defects in type III collagen are often expressed in the vessel walls, 31 where the tissue is exposed to large changes in intraluminal pressure.
In this study, we divided the tissue into 3 fractions: a soluble tissue extract and noncalcified and calcified insoluble matrixes. The noncalcified and calcified fractions were studied separately to obtain information on the possible effect of the calcification process on collagen. Interestingly, there were no differences between these fractions with respect to the proportions of type I and type III collagens. Calcification in the vessel wall is inhibited by the matrix Gla protein, 32 and this seems to be a totally different process from the mineralization of the organic matrix of bones, where practically only type I collagen is normally present. The fully matured state of the cross-links in type I collagen of the vessel wall also differs from the situation in mineralized bone collagen. 30 Partially processed type III procollagen molecules with a retained amino-terminal propeptide (ie, type III pN-collagen) are found in most tissues on the surface of type III collagen fibers by immunohistochemical analyses. Here, 1 ⁄3 of such type III pN-collagen molecules could be easily extracted from the atherosclerotic plaques, indicating that these molecules did not yet participate in intermolecular cross-linking, which is essential for the tensile strength of the tissue. The rest of the type III pN-collagen was found in the insoluble matrix, but the total amount of type III pN-collagen in type III collagen was still negligible ( Table 2 ). The estimation of the amount of PIIINP in the insoluble matrix was based on the surprising finding that a definite part of its immunoreactivity is retained after heat denaturation and trypsin digestion (Figure 4 ). The PIIINP propeptide is stabilized by 3 interchain and 5 intrachain disulfide bridges. Consequently, the melting temperature of the collagenous domain is as high as 53°C, and refolding of the helix from the denatured peptide takes place extremely fast, as the chains are held together by the disulfide bonds. 33 Our results suggest that only 1 of the 3 chains of the PIIINP molecule is susceptible to trypsin (Figure 3 ), although all 3 chains have 3 arginine and 2 lysine residues, which are potential trypsin digestion sites. The reason for this trypsin resistance is unknown, but there are several possibilities. The rapid refolding of the helix may protect the sites within the collagenous domain, because trypsin does not cleave triplehelical collagen; alternatively, lysines in the collagenous domain can be hydroxylated to hydroxylysine residues. One arginine is very close to a tyrosine residue in the aminoterminal part of the propeptide that can be sulfated to tyrosine-O-sulfate. 34 This highly negative charge may alter the molecule's susceptibility to trypsin. In any case, there was very much less type III pN-collagen in the plaques than could be expected. The proportion of type III pN-collagen was as much as 1000-fold higher in human placenta, representing fetal tissue. Also, in rapidly growing human uterine leiomyoma, this proportion was 1.4%.
Previous studies have suggested that fibrinolytic enzymes play a significant role in the processing and turnover of collagen in the vessel walls. 12, 13 On the other hand, thrombin, for example, stimulates SMC procollagen synthesis, 35 which could indicate that the development of pathological conditions involving the blood coagulation system would rather lead to increased connective tissue deposition than to its slower-than-normal degradation. We could find only relatively small concentrations of free procollagen propeptides (Figure 6 ), which are directly related to ongoing collagen synthesis, and our data thus support the idea of metabolic inertia. 36 These propeptide domains of interstitial procollagens are removed by specific endoproteinases (C-and N-proteinases) in the extracellular space. Above all, the complete processing of type III collagen in the atherosclerotic plaques is surprising and raises interesting questions. The thrombogenicity of type III collagen in the vessel wall must thus be based on fully processed and cross-linked collagen, and clinical events such as rupture of the plaque must involve the degradation of such collagen molecules. The turnover and processing of type III collagen may well be different in several other pathological situations and also related to their pathogenesis.
